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Summary The derivation of permanent cell lines from 40 resected oesophageal carcinomas has been attempted. Five long-term lines have
been established from three adenocarcinomas, one mixed carcinoma and one squamous carcinoma. Molecular and cellular analyses have
been carried out on the lines and clones derived from them. Karyotype analysis indicates genetic variation among the clones. HLA-A, -B and
-C is expressed constitutively, but not HLA-DR. ICAM-1-expressing phenotypes may have arisen during adaptation to long-term culture. All
lines are capable of response to interferon-y (IFN-y) and all produce transforming growth factor f1 (TGF-f1). Two lines are resistant to the
inhibitory growth effects of the latter, possibly contributing to malignancy. It is anticipated that these lines, originating from histologically
different carcinomas, will provide a valuable, continuous resource for the investigation and treatment of these aggressive tumours.
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Oesophageal carcinoma is an aggressive disease with an overall
5-year survival rate of less than 4% (Matthews et al, 1987a). Its
incidence has increased in many areas, with a 44% increase in
the West Midlands, UK, between the periods 1962-1966 and
1977-1981 (Matthews et al, 1987b) and a doubling of the inci-
dence rate of adenocarcinoma among white males in the USA
between 1976 and 1987 (Blot et al, 1991). Multimodality regi-
mens, now being developed, are however proving to be of some
value in the treatment of the disease (Coia and Sauter, 1994). An
improved understanding of the molecular, cellular and immuno-
logical mechanisms, which lie behind the progression of
oesophageal carcinoma, is required for the development of more
efficacious treatments. This could in part be achieved by the
study in vitro of cells derived from tumours, ideally in primary
culture, mimicking the in vivo situation. This has been possible
with some cancers (e.g. colorectal: Donnellan et al, 1995) with
cells capable of prolonged survival in vitro. In our experience,
cells derived from oesophageal tumours die very rapidly in
primary culture.
Permanent cell lines derived from other cancers have proved
to be of value as an experimental source, but few oesophageal
lines have been developed in laboratories outside the Orient
(these last being exclusively squamous in origin) (Jankowski et
al, 1995).
We have undertaken the establishment of permanent cell lines
derived from oesophageal carcinoma ofvarious histological types
to provide a long-term source ofexperimental material. Molecular





Correspondence to: S J Darnton
MATERIALS AND METHODS
In vitro establishment and culture of cell lines
The lines were established from samples ofapproximately 0.5 cm3
cut from a leading edge of the tumour of freshly resected speci-
mens and placed in 10-20 ml of ice-cold tissue culture medium
[DMEM, bicarbonate-buffered Dulbecco's modified Eagle
medium (Gibco-BRL) supplemented with 10% (v/v) fetal calf
serum (FCS) (Sigma), L-glutamine (2 mM), penicillin (500 IU
ml-'), streptomycin (500 gg ml-') and amphotericin B (Gibco
BRL; 5 gg ml-')]. The samples were washed several times by
vigorous shaking in phosphate-buffered saline (PBS), finely
minced and digested [with gentle agitation (RIOO Rotary Shaker,
Luckham Ltd)] in 10 ml of DMEM (to which collagenase, 1 mg
ml-', DNAase, 0.02 mg ml' and hyaluronidase, 0.01 mg ml-'; all
Boehringer-Mannheim, had been added) for 16-20 h at room
temperature.
Both tissue culture Petri dishes (Nunc) and collagen-coated
(type IV human placental collagen, Sigma) standard Petri dishes
(Sarstedt) containing 10 ml of DMEM were used for long-term
culture with incubation at 37°C in a humidified incubator
containing 5% carbon dioxide in air. Primary cultures were left
undisturbed for at least 5 days. Ifepithelial colonies developed, the
old medium was aspirated and fresh medium added every 2-4
days. Fibroblasts, spreading during early primary culture, were
removed using cell scrapers (Costar). When the epithelial cells had
grown sufficiently, they were transferred selectively to fresh
culture vessels using Dispase (2 U ml-', Boehringer Mannheim).
The established lines (cells routinely subculturable and free of
visible fibroblast contamination) were incubated in tissue-culture
grade flasks (Nunc) at 37°C, with medium changes at 2-3 day
intervals. Upon reaching confluence, cells were passaged by
trypsinization (Trypsin-EDTA, Gibco-BRL).
Cell lines were tested for the presence ofMycoplasma spp. and
found to be free ofcontamination.
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Xenografts in nude mice
Four cell lines (JROECLl9, JROECL21, JROECL33 and
JROECL47) were checked for the ability to develop as tumours in
nude (nu/nu) mice. Two million cells were injected subcuta-
neously into the back of 7-week-old males (Harlan) at the
following points: JROECL19, 15th passage, JROECL21, 11th
passage, JROECL33, 3rd and 14th passages and JROECL47, 5th
passage. Numbers and time of development of tumours at or near
the site of injection were noted. The animals were culled as soon
as tumour growth was confirmed.
Preparation of clones from primary cell lines
Cell line clones were developed from early passage (<5 passages)
parental lines. Parental lines were diluted to 5, 10 or 50 cells per
ml in culture medium. Samples of 100 ,l of suspension were
placed in each well of a 96-well, flat-bottomed microtitre plate
(Nunclon). Wells containing a single cell were marked, incubated
at 37°C and checked weekly until the expanded colonies could be
transferred to progressively larger wells. When confluence was
reached, the cells were transferred to culture flasks.
Chromosome analysis
An 80% confluent monolayer from each clone was treated with
0.02 mg ml-' colchicine (Fluka) for 3-4 h at 37°C. Dividing
(rounded) cells were dislodged from the substrate by tapping the
culture flask sharply and harvested by centrifugation. The cell
pellet was resuspended in 10 ml of hypotonic potassium chloride
(0.05 M) for 10 min at room temperature and fixed in ice-cold
ethanol/glacial acetic acid (3:1) for 30 min. Chromosome spreads
were prepared by dropping 20 ,ul of cell suspension on to dry,
ethanol-cleaned slides.
Surface antigenic phenotype
The constitutive antigenic profiles of the lines (and clones of line
21) were determined by flow cytometric analysis (FCA)(FACStar,
Becton Dickinson) using standard procedures. Data were analysed
using the Becton Dickinson Consort 30 program. The following
fluorescein-conjugated murine monoclonal anti-human antibodies
were used: HLA-A,-B,-C (MHC class I)(Dako), HLA-DR (MHC
class II)(Becton Dickinson), ICAM-1 (CD54)(Serotec), with IgG-
negative controls (Becton Dickinson).
Cytokine treatment of cell lines and clones of cell
line 21
Cells (1 x 105) in 2 ml of medium were seeded into each well of a
six-well flask. Recombinant human interferon-y (IFN-y) and/or
transforming growth factor P1 (TGF-1) were/was added to a
concentration of 100 U ml-' (IU IFN-y= 100 pg; 1 UTGF-Pl = 50
pg), with incubation at 37°C for 72 h before harvesting and
labelling for analysis by FCA.
Determination ofTGF-p1 sensitivity by [3H]thymidine
incorporation assay
Cells were seeded at 104 cells per well in 100 ,l of medium in 96-
well microtitre plates (Nunc) and incubated at 37°C, with 5%
carbon dioxide in a humidified atmosphere. At 70-80% conflu-
ence, the medium was replaced by 100 ,l of fresh medium with
1% FCS containing natural humanTGF-P1 (R&D Systems) added
at concentrations of 0, 5, 50 or 500 pg ml'. Multiple runs, with
five replicates in each, were used for each dilution. Following
overnight incubation, I gCi of [3H]thymidine (Amersham) in 10
,ul ofmedium (1% FCS) was added to each well. After 6-12 h, the
medium was aspirated and the cell monolayers fixed in cold (4°C)
5% (w/v) trichloroacetic acid (BDH). After rinsing in sterile
distilled water (4°C), the cells were dissolved in 100 ,ul of IM
sodium hydroxide by incubation at 37°C for 60 min. The resulting
solution was added to 4 ml of scintillation fluid (Optiphase 'Safe',
LKB) and the [3H]thymidine incorporation counted on a 12/9
Rackbeta scintillation counter (Wallack LKB).
Analysis ofTGF-p1 production by the cell lines
Cells (2 x 105) in 2 ml ofculture medium were added to one well of
a six-well flask (Nunc) and incubated under standard conditions
until 80% confluent. The conditioned overlying medium was
removed, centrifuged to remove non-adherent cells and debris and
frozenat -80°C. Two millilitres of medium without FCS was added
to the cells and after incubation for 24 h at 37°C, the medium was
removed, centrifuged and frozen as before. Enzyme-linked
immunosorbent assay (ELISA) analyses of the cell supematants
werecarried out using theTGF-PI 'Quantikine' kit (R&D Systems).
mRNA extraction from cell monolayers and
suspensions
This was carried out using Dynal's Dynabead mRNA Direct kit.
Table 1 Long-term oesophageal carcinoma cell lines
Line Original histology Differentiation Stage (UICC) Age of patient Sex of patient Age of linea
JROECL19 Adenocarcinoma of cardia Moderate III 72 M 19(31)
JROECL21 Squamous Moderate IIA 74 M 17(44)
JROECL24 Adenocarcinoma in Barrett's Poor IIB 68 M -
JROECL33 Adenocarcinoma in Barrett's Poor IIA 73 F 14(19)
JROECL47 Squamous with focal adenocarcinoma Poor IIA 76 M 8(25)
JROECL50 Adenocarcinoma Moderate to poor IIA 71 F 8(19)
aAge of line at 30 September 1994 to nearest month (number of subcultures). - Senesced after three passages.
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Reverse transcription-polymerase chain reaction
(RT-PCR)
A master mix of reverse transcription (RT) reagents was prepared
containing: 1 x RT buffer (50 mm Tris.Cl pH 8.3, 75 mm potassium
chloride, 3 mm magnesium chloride; Gibco-BRL), 10 mM DTT,
0.5 mM dNTPs (Pharmacia), 2.5 mM oligo dT18 primer, 40 U
RNAsin (Promega) and 25 U MMLV-RT (Gibco-BRL). Between
100 and 500 ng ofmRNA was added following incubation at 600C
for 5 min (to denature secondary structure) and the reaction
volume adjusted to 20 ,ul with sterile distilled water. The reaction
mix was overlaid with 100g1 ofparaffin oil and incubated at 37°C
for 60 min followed by 5 min at 99°C.
Completed RT reaction mix (2 gl) was transferred to a 100 gl
polymerase chain reaction (PCR). For each RT sample, a PCR
master mix was prepared from: 1 x PCR buffer1(50 mM Tris-Cl pH
8.3, 75 mm potassium chloride; Gibco-BRL), 12.5 mm magnesium
chloride, 0.2 mM dNTPs, 50 pmol of each primer (sense: 5'-
CTGCGGATCTCTGTGTCATT-3', antisense: 5'-CTCAGAGT-
GTTGCTATGGTG-3'), 2.5 U Amplitaq DNA polymerase and
sterile distilled water to give a final volume of 98 g1. A two-step
t w o -
stage PCR programme was used for TGF-P1 amplification: 95°C
for 1 min, 65°C for 1 min (34 cycles) followed by one cycle of95°C
for 1 min and 65°C for 7 min.
RESULTS
In vitro establishment of cell lines
Forty tumours were placed into culture. In about half, outgrowth,
sometimes quite extensive, of epithelial cells was observed but in
most cases the cells did not survive the first subculture. Ofthe six
that did (Table 1), five have now been maintained for more than 20
consecutive subcultures and may be regarded as permanent (a
'success' rate of 5/40, i.e. 12.5%). The five lines all show epithe-
lial morphology (JROECL21 is pictured in culture in Figure 1) and
express epithelial cytokeratins. All lines grow as islands ofpolyg-
onal cells, but each is morphologically distinct.
Xenografts in nude mice
Four lines were tested and shown to be tumorigenic, with subcuta-
neous tumours developing in less than 3 weeks in 4/4
(JROECL19), 5/5 (JROECL21) and 3/3 (JROECL47) mice.
Figure 1 Morphology of JROECL21 in culture. The cell line shows epithelial
morphology and is pleomorphic with some multinucleate giant cells (arrow)
JROECL33 (3rd passage) did not produce tumours at the first
attempt, but did so in 3/3 mice following further culture (14th
passage) in vitro. JROECL24 senesced and was not tested.
JROECL50 was not tested.
Karyotyping
All the lines and clones that were examined showed aberrant kary-
otypes. JROECL19, 21 and 33 were all grossly aneuploid (near
tetraploid). JROECL47 and 50, which were near diploid, were
examined more closely. JROECL47 was characterized by loss of
chromosome 17 and frequent double minutes, seen also in clones
from this line. JROECL50 exhibited frequent loss ofchromosomes
3, 5 and 17, but no double minutes. Translocations (2p;9p, 2q;17p
Table 2 Constitutive and IFN-y-inducible expression of HLA and ICAM-1 in cell lines and effect of TGF-,1 on IFN-y-induction
Line HLA-A, -B and -C HLA-DR ICAM-1
Constt Const' Induc TGF-,B1 Constt Const' Induc TGF-,B1 Constt Const' Induc TGF-B1
JROECL19 + + + NE - - +s NE - - + NE
JROECL21 +/- + + NE - - - NE - - + NE
JROECL24 - + + N/A - - - N/A - + + N/A
JROECL33 + + + R +/- - + NE + + + NE
JROECL47 + + + NE - - +s NE - - +s NE
JROECL50 + + + NE - - +s NE - - + NE
Constitutive expression of HLA and ICAM-1 in the primary tumours is also shown. Constt, constitutive expression in primary tumours; Const', constitutive
expression in cell lines; Induc, inducible expression; +s, inducible in a subpopulation; TGF-,1l, effect ofTGF-l1 on IFN-y-induced expression. N/A, not
assessed; NE, no effect; R, reduced induction.
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Figure 2 Five replicate cultures of the cell lines were treated with graded doses of TGF-,Bl and then incorporation of [3H]thymidine (c.p.m., mean c.p.m. per
culture) was measured. Bars indicate incorporation. T, standard deviation. *, difference compared with no TGF-f1 was significant at the P < 0.05 level (Student's
t-test)
2q;13q) were observed in some ofthe clones from JROECL50.
Surface antigenic phenotype and cytokine treatment
The surface antigenic properties and results ofcytokine treatment
of JROECL19, 21, 24, 33, 47 and 50 and of JROECL21 cell line
clones are summarized in Tables 2 and 3. A previous study
(Rockett et al, 1995) has investigated immunohistochemically the
surface antigenic phenotype of the primary tumours from which
the cell lines were derived. This is also shown in Table 2.
Determination of the effect ofTGF-p1 on growth of cell
lines
Replicate cultures of the cell lines were treated with graded
doses of TGF-41. The incorporation of [3H]thymidine was then
measured in order to determine the growth-inhibitory effects of
this cytokine on the cells. Representative data for all five lines are
shown in Figure 2. Some variation of response was seen from
experiment to experiment, perhaps because of different in vitro
passage levels used. However, all cell lines seemed to show some
degree of inhibition, although in the case of JROECL50 this
was small and not statistically significant, even at the highest
TGF-P1 concentration used in this particular experiment. Lines
JROECL19, 21 and 33 seemed more sensitive and 47 and 50 rela-
tively less sensitive.
Analysis ofTGF-01 production by the cell lines using
ELISA and RT-PCR
Table 3 Constitutive and IFN-y-inducible expression of HLA and ICAM-1 in JROECL21 cell line clones and effect ofTGF-f1 on IFN-y induction
Clone HLA-A-B and-C HLA-DR ICAM-1
Const Induc TGF-,B1 Const Induc TIGF-P1 Const Induc TGF-,B1
21c1 + + NE - +s NE - +s NE
21c2 + + NE - - NE - + NE
21c3 + + NE - + NE - - NE
Const, constitutive expression; Induc, inducible expression; +s, inducible in a subpopulation; TGF-13l, effect ofTGF-f1 on IFN-y-induced expression.
NE, no effect.
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Table 4 TGF-f1 production by cell lines






a10% FCS in medium. Values corrected forTGF-p1 activity of serum. bNo
FCS in medium.
Supernatants from lines cultured in the presence and absence of
serum (which both contains TGF- 1 and stimulates its production
by some cells; Danielpour, 1993) were analysed for TGF-f1
(Table 4). Clones derived from JROECL21 produced varying
amounts of TGF- 1 (data not shown). RT-PCR of extracted
mRNA demonstrated the presence of TGF- 1 mRNA in cells of
all five lines (data for three ofthese lines are shown in Figure 3).
DISCUSSION
The original aim of this work, to study primary cell cultures of
oesophageal tumours as a model for behaviour in vivo, was impos-
sible because of the rapid death of the cells in vitro. It was,
however, possible to derive five long-term cell lines. Since origi-
nating samples were taken from the leading edge of tumours, it is
possible that the lines could derive from normal epithelial cells
included in the samples. This is, however, unlikely since the lines
are aneuploid and tumorigenic and must presumably be derived
from malignant cells. Furthermore, 40 attempts at direct culture of
grossly normal oesophageal epithelium from a site distant from the
tumour failed to give rise to permanent cell lines. The success rate
for establishing our lines was 12.5%, which falls within the range
of rates (6-28%) reported for the establishment of long-term lines
from various human tumours (Shimada et al, 1992). In our hands,
the use of feeder cells or collagen-coated tissue culture flasks (as
an alternative to standard tissue culture flasks) did not result in
improved cell attachment and growth.
The analysis of clones of parent lines provides a means to
explore the phenotypic variants, which exist in oesophageal carci-
noma. The possibility that variations may be due to differentiation
or transformation during in vitro culture is, ofcourse, inescapable.
Preliminary analysis of karyotypes indicates that there is genetic
variation among the clones, and this would be expected to be
reflected in phenotypic variation. The studies of HLA expression,
response to cytokines and production of TGF- 1 have, however,
only revealed minor variations.
All the lines express HLA-A, -B and -C antigens constitutively,
although rather weakly in one case (JROECL19). However, since
the antibody used recognizes monomorphic determinants, we
cannot exclude the situation of specific alleles having been lost by
the cells (documented in other tumours; Garrido et al, 1993). None
of the lines expressed HLA-DR constitutively, but two expressed
ICAM-I. The latter result was unexpected, since we have shown
previously that ICAM-1 is not expressed by oesophageal epithelial
cells under normal conditions (Rockett et al, 1995). These ICAM-
1-expressing phenotypes may have arisen during the process of
adaptation to long-term culture. Immunohistochemistry ofthe cell
surface antigenic phenotype of the original tumours from which
Figure 3 Agarose gel of RT-PCR products obtained from mRNA (100 ng)
of three of the cell lines with controls. Lanes 1-10: 1-kb ladder; JROECL21;
JROECL47; JROECL50; cell line KHos; 100 fg of shortened synthetic
TGF-,1 RNA; RT-negative control (no RNA); PCR-negative control
(no DNA); PCR-positive control (TGF-1l plasmid DNA); 1-kb ladder.
* = 298 bp; ** = 220 bp
the cell lines were developed has shown previously that there was
little apparent surface expression on the cells; staining, although
occasionally membranous, was mainly cytoplasmic. Comparison
ofthe phenotypes ofthe primaries and their derived lines reveals a
fairly consistent expression. There were the following inconsisten-
cies. Two lines, (from one heterogeneous tumour and from one
negative tumour) expressed HLA-A, -B and -C. One line (from a
heterogeneously expressing tumour) was negative for HLA-DR.
The ICAM-1-expressing lines were derived from a negative and
a positive primary. Changes in phenotype could have occurred in
the process of establishment into culture, perhaps as a result of
clonal development from a heterogeneous primary in some cases,
or because of the withdrawal of in vivo local suppressive factors
in others.
All the lines were sensitive to IFN-y, expressing enhanced levels
of HLA-A, -B and -C antigens and ICAM-1 and, in 4/6 cases,
HLA-DR. The lines are thus able to respond to IFN-y with
enhanced expression of these surface antigens, essential for
immune recognition. It does not, however, follow that the cells of
the original tumour in vivo would be capable of such a response.
TGF-I is a pleiotropic cytokine with multiple effects on
tumorigenesis, e.g. as an inhibitor ofgrowth (Massague, 1990), on
angiogenesis (Roberts et al, 1986), on immune responses (Wrann
et al, 1987) and as an inhibitor of the induction of HLA-DR anti-
gens by IFN-y (Darley et al, 1993). Our data indicate that, in
common with many other neoplastic and normal cell types,
oesophageal carcinoma cells produce TGF-,BI. Three of the five
lines showed some of the expected inhibition of growth in
response to TGF-fI but two lines appeared resistant, while them-
selves producing the greatest amounts of the cytokine. In the
evolution of these two tumours, the augmented production of
TGF-f 1 and the development ofresistance to its growth-inhibitory
effects possibly contributed to the malignancy of the cells. Owing
to small numbers, we cannot say whether this is a common feature
of oesophageal carcinomas. In only one line did TGF-Pl have an
effect on induction ofsurface antigens by IFN-y: a small inhibition
of HLA-A, -B and -C induction. It therefore seems unlikely that
production of TGF-31 by oesophageal carcinoma cells influences
the surface antigen response induced by IFN-y. TGF-01 produc-
tion by tumours could, however, provide a selective host immunity
escape advantage by other mechanisms, such as inhibition of
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proliferation, cytokine production or cytotoxic function, or induc-
tion ofanergy or apoptosis of inflammatory cells.
It would be of interest to search further for clonic differences in
the production of TGF- 1 and other cytokines. It now appears
possible that when clones differentiate along separate pathways
they may produce growth factors (e.g. acidic fibroblast growth
factor; Jouanneau et al, 1994), which serve as a means to progress
the whole tumour 'community', rather than merely conveying an
individual clonal survival advantage. A community effect of cell
interactions could account for the development ofa heterogeneous
cell population, rather than the emergence of clonal dominance
during tumorigenesis. Oesophageal carcinomas do show multi-
directional morphological differentiation (Newman et al, 1992).
The long-term oesophageal carcinoma lines described here
represent a potentially important development, since there have
been few reports of such continuous lines, these almost all
produced in China, Japan, South Africa or the USA (Jankowski et
al, 1995). The five lines have been deposited with the European
Collection of Cell Cultures (ECACC), which, at February 1996,
had no human oesophageal cancer lines on deposit. The existence
of a European stock (with their derived clones) originating from
histologically different carcinomas provides a valuable resource
for the investigation of oesophageal tumour immunology, its
possible modulation and also the response and resistance to treat-
ment regimens.
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